Kelifarma - Company finances
|
EUR
|
2019
From: 2019-04-15
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 2,500 | 400 | - | - | - | 22,734 | 462,267 |
| Profit before tax | 682 | -6,229 | -4,434 | -3,363 | -15,724 | 3,210 | 0 |
| Net profit | 648 | -6,229 | -4,434 | -3,363 | -15,724 | 3,210 | 0 |
| Equity | 3,148 | 144,419 | 139,985 | 136,622 | 120,898 | 124,108 | 124,108 |
| Liabilities | 6,702 | 8,726 | 105,875 | 96,806 | 66,249 | 40,651 | 93,055 |
| Non-current assets | 0 | 0 | 0 | 35,638 | 18,619 | 1,599 | 48,707 |
| Current assets | 9,850 | 153,080 | 385,395 | 374,037 | 168,528 | 163,160 | 831,145 |
| Total assets | 9,850 | 153,080 | 385,395 | 409,675 | 187,147 | 164,759 | 879,852 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 20 | 147 | 26,463 |
| Social insurance contributions | - | - | - | - | - | 111 | 48,752 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | -84.0% | - | - | - | - | +1933.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 6.6% | -4.1% | -1.2% | -0.8% | -8.4% | 1.9% | 0.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 20.6% | -4.3% | -3.2% | -2.5% | -13.0% | 2.6% | 0.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 25.9% | -1557.3% | - | - | - | 14.1% | 0.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 27.3% | -1557.3% | - | - | - | 14.1% | 0.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.1 | 0.1 | 0.8 | 0.7 | 0.5 | 0.3 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,500 | 400 | - | - | - | 10,873 | 50,892 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Kelifarma - Social security debts
The amount of overdue SODRA debt for the company Kelifarma as of the last working day is: 852 €
| From | To | Debt, € |
|---|---|---|
| 2026-10-07 | 2026-10-09 | 852.11 |
| 2026-10-03 | 2026-10-05 | 852.11 |
| 2026-09-26 | 2026-09-28 | 852.11 |
| 2026-09-20 | 2026-09-21 | 852.11 |
| 2026-09-16 | 2026-09-17 | 852.11 |
| 2026-09-05 | 2026-09-09 | 74.19 |
| 2026-08-23 | 2026-09-02 | 74.19 |
| 2026-08-18 | 2026-08-19 | 74.19 |
| 2026-07-28 | 2026-08-09 | 74.19 |
| 2026-07-27 | 2026-07-27 | 19841.04 |
| 2026-07-26 | 2026-07-26 | 19766.85 |
| 2026-07-23 | 2026-07-25 | 19841.04 |
| 2026-07-19 | 2026-07-22 | 19766.85 |
| 2026-07-16 | 2026-07-17 | 19766.85 |
| 2026-06-25 | 2026-07-15 | 7792.06 |
| 2026-06-16 | 2026-06-24 | 11893.68 |
| 2026-02-18 | 2026-02-22 | 11231.09 |
| 2026-01-16 | 2026-01-26 | 1104.84 |
| 2025-08-20 | 2025-08-26 | 227.53 |
| 2025-07-25 | 2025-08-10 | 3.36 |
| 2025-07-24 | 2025-07-24 | 226.83 |
| 2025-07-16 | 2025-07-23 | 223.47 |
| 2025-06-17 | 2025-06-25 | 470.64 |
| 2025-05-27 | 2025-05-29 | 355.55 |
| 2025-05-16 | 2025-05-26 | 380.18 |
| 2025-04-30 | 2025-04-30 | 122.24 |
| 2025-04-28 | 2025-04-29 | 123.62 |
| 2025-04-26 | 2025-04-27 | 122.24 |
| 2025-04-24 | 2025-04-25 | 123.62 |
| 2025-04-16 | 2025-04-23 | 122.24 |
| 2025-03-19 | 2025-04-15 | 90.46 |
| 2025-02-18 | 2025-03-18 | 58.68 |
| 2025-01-22 | 2025-02-17 | 28.44 |
| 2025-01-16 | 2025-01-21 | 27.33 |
| 2024-12-22 | 2024-12-26 | 85.32 |
| 2024-12-17 | 2024-12-20 | 85.32 |
| 2024-11-18 | 2024-12-16 | 57.99 |
| 2024-11-04 | 2024-11-17 | 29.78 |
| 2024-10-29 | 2024-11-03 | 54.05 |
| 2024-10-28 | 2024-10-28 | 52.48 |
| 2024-10-24 | 2024-10-27 | 54.05 |
| 2024-10-16 | 2024-10-23 | 52.48 |
| 2024-09-17 | 2024-10-15 | 24.27 |
| 2024-07-24 | 2024-09-02 | 98.44 |
| 2024-07-16 | 2024-07-23 | 97.17 |
| 2024-06-18 | 2024-07-15 | 72.90 |
| 2024-05-16 | 2024-06-17 | 48.63 |
| 2024-04-23 | 2024-05-15 | 24.36 |
| 2024-04-16 | 2024-04-22 | 24.27 |
| 2024-03-18 | 2024-03-27 | 24.61 |
| 2024-02-19 | 2024-03-17 | 0.34 |
| 2022-12-16 | 2022-12-21 | 425.56 |
| 2022-10-18 | 2022-10-27 | 648.16 |
| 2022-05-17 | 2022-05-25 | 930.13 |
| 2022-04-25 | 2022-05-16 | 169.40 |
| 2022-04-19 | 2022-04-24 | 166.54 |
| 2022-03-22 | 2022-04-04 | 56.23 |
| 2022-03-16 | 2022-03-21 | 904.27 |
| 2022-01-27 | 2022-02-21 | 12.26 |
| 2021-11-22 | 2021-11-22 | 12.91 |
| 2021-11-16 | 2021-11-21 | 3101.81 |
| 2021-11-09 | 2021-11-15 | 12.91 |
| 2021-10-18 | 2021-10-20 | 3204.78 |
Kelifarma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-09-16 | 2026-09-19 | 632.62 |
| 2026-08-16 | 2026-08-19 | 79.1 |
| 2026-08-02 | 2026-08-10 | 718.77 |
| 2026-07-17 | 2026-08-01 | 709.87 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Kelifarma, UAB (code 305133484) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of €462.3K, compared with €22.7K in 2024, indicating very strong year-on-year growth of 1933.4%. The latest available net profit figure is from 2024, when the company posted €3.2K in profit after a €15.7K loss in 2023; the 2024 profit margin was 14.1%. For 2025, profitability is not disclosed, but the revenue expansion was accompanied by a larger balance sheet: total assets increased to €879.9K from €164.8K in 2024, while equity remained at €124.1K and liabilities rose to €93.1K. The equity ratio stood at 14.1%, debt-to-equity at 0.75, and asset turnover at 0.53x. Revenue per employee was €51.4K, suggesting moderate operating productivity relative to the reported scale of activity.